Fibrinolytic therapy in left side-prosthetic valve acute thrombosis. In depth systematic review.

Background: Limited data are available on the impact and safety of fibrinolytic therapy (FT) in left - side prosthetic valve acute thrombosis (PVAT).

Study Objective: To improve our knowledge about the FT role in left -side PVAT.

Design: Bibliographic search and analysis.

[Alteplase in acute coronary syndromes].

Objective: The registry intends to establish the safety and security of one-hour 100 mg alteplase infusion and 50 mg in 30 minutes to facilitate percutaneous coronary intervention (PCI) in a cardiology hospital with primary angioplasty program (24 hours 365 days a year) with current doses of unfractionated heparin and enoxaparin.

Methods And Results: REALSICA II is a prospective registry that included 103 patients with final diagnosis of ST elevation myocardial infarction in which Alpert's quality criteria were used. Seventy two patients were under one-hour 100 mg alteplase infusion and thirty one under 30 minutes 50 mg alteplase infusion to facilitate PCI.

[Risk marker stratification in coronary acute syndromes].

Acute coronary syndromes have a heterogeneous clinical presentation with a broad spectrum for mortality and adverse events. It is mandatory to identify high risk groups for percutaneous coronary intervention and intensive antithrombotic treatment or common risk for standard treatment. In contemporaneous medicine it is important to get adequate risk stratification because the impact of hospitalary costs, antithrombotic and reperfusion treatment on health systems.

[Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction].

The main targets in reperfusion strategies in early ST-T elevation acute myocardial infarction phase are to improve and sustain tisular perfusion. Due to its accessibility and effectiveness in reducing myocardial damage and mortality, fibrinolytic therapy has been considered as the standard treatment. The most serious fibrinolytic therapy dilemma is the high failure and reocclusion rate, secondary to resistance and rethrombosis phenomena.